NCT07514169
- Conditions
- Large B-Cell Lymphoma (LBCL)
- Locations
-
- Ruijin Hospital Shanghai, China
Clinical trial condition
Large B-Cell Lymphoma (LBCL)
Explore clinical trials studying Large B-Cell Lymphoma (LBCL). Study availability and eligibility vary by location and protocol.
10 public trials
4 recruiting studies
Large B-Cell Lymphoma (LBCL) trial results
NCT07361224
- Conditions
- Large B-Cell Lymphoma (LBCL)
- Locations
-
- Sourasky Medical Center Tel Aviv, Israel
Recruiting
Real World Practice With Academic Anti CD19 CAR-T Cell Therapy in Relapse/Refractory B-cell Lymphoma
NCT07524816
- Conditions
- Large B-Cell Lymphoma (LBCL)
- Locations
-
- NN Alexandrov National Cancer Centre of Belarus Lyasny, Minsk Oblast, Belarus
NCT04661020
- Conditions
- Large B-Cell Lymphoma (LBCL)
- Locations
-
- The First Affiliated Hospital，College of Medicine, Zhejiang University Hangzhou, Zhejiang, China
NCT07717177
- Conditions
- Large B-Cell Lymphoma (LBCL)
- Locations
-
- Ruijin Hospital Shanghai, China
Not Yet Recruiting
AI-Driven Treatment Strategy vs Pola-R-CHP in Untreated LBCL
NCT07594899
- Conditions
- Large B-Cell Lymphoma (LBCL)
- Locations
-
- Ruijin Hospital, Shanghai Jiao Tong University School of Medicine Shanghai, Shanghai Municipality, China
Not Yet Recruiting
Emapalumab Prophylaxis of Bispecific T-Cell Engagers (BiTEs) Associated CRS and ICANS
NCT07567014
- Conditions
- Blood Protein Disorders, Cardiovascular Diseases, Hematologic Diseases, +13 more
- Locations
-
- NYU Langone Health Perlmutter Cancer Center - Sunset Park Brooklyn, New York, United States
- NYU Langone Health Perlmutter Cancer Center - Manhattan Manhattan, New York, United States
- NYU Langone Health - Long Island Mineola, New York, United States
Not Yet Recruiting
Exploratory Clinical Study on the Safety and Efficacy of CD19X CAR-T Cell Injection in the Treatment of Relapsed/Refractory Large B-Cell Lymphoma
NCT07447726
- Conditions
- Disease Attributes, Large B-Cell Lymphoma (LBCL), Pathologic Processes, +2 more
- Locations
-
Not specified
Not Yet Recruiting
Golcadomide, Poseltinib, and Rituximab for Relapsed/Refractory Diffuse Large B-cell Lymphoma
NCT07269639
- Conditions
- Large B-Cell Lymphoma (LBCL)
- Locations
-
- Seoul National University Hospital Seoul, South Korea
Active, Not Recruiting
CD19/ CD22 Bispecific CAR-T Cell Therapy for Relapsed/ Refractory Large B-cell Lymphoma
NCT07461831
- Conditions
- Large B-Cell Lymphoma (LBCL)
- Locations
-
- Beijing Tongren Hospital, Capital Medical University Beijing, Beijing Municipality, China